For example, in the study of genomic biomarker heterogeneities between SARS-CoV-2 and COVID-19, genes (ABCB6, KIAA1614, MND1, SMG1, RIPK3, CDC6, ZNF282, CEP72, ATP6V1B2, IFI27, BTN3A1, SERTAD4, and EPSTI1) had robust and nearly perfect performance among 15 cohorts (including different ethics, SARS-CoV-2 subvariants, e.g., omicron, breakthrough infections) with thousands of samples [10], which further led to a confirmation of MND1, CDC6, ZNF282, ATP6V1B2, and IFI27 being meaningful for discovering vaccine adverse effects among COVID-19-convalescent octogenarians [11]. This evidence concerns the gene ABCB6 and COVID-19.